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EDITORIAL REVIEW
The kidney in mitochondrial cytopathies
Mitochondrial cytopathies are a heterogeneous group of dis-
eases that are characterized by defects of oxidative phosphoryla-
tion which can affect several organs or tissues [1, 21. The mito-
chondrial respiratory chain has a major role in ATP production
during aerobic respiration [31. Genetic defects of one or several
polypeptide enzyme complexes of the oxidative phosphorylation
system can give rise to mitochondrial diseases [4]. Since the
original report by Luft et al [5], these disorders have long been
regarded as neuromuscular diseases only. Mitochondrial myopa-
thies were first defined by the ragged red fiber in biopsied skeletal
muscle, using the modified Gomori trichrome stain, with accumu-
lation of abnormal mitochondria. A number of other organs,
including heart, liver, pancreas, hematopoietic system and kidney,
are dependent upon mitochondrial energy supply and can there-
fore be affected during the course of these disorders [6]. Indeed,
a broad spectrum of clinical symptoms have been reported in
these patients. Renal involvement have occasionally been re-
ported. In a previous study including 66 adult patients with
mitochondrial disorders, only one patient presented with renal
disease [7]. In contrast, renal symptoms appear to be more
common in children with such diseases.
Mitochondrial respiratory chain
The mitochondrion has a major role in fatty acid oxidation,
tricarboxylic acid cycle, urea cycle and also ATP production
through the process of oxidative phosphorylation. Oxidative phos-
phorylation occurs at the level of the respiratory chain in the inner
membrane of the mitochondrion. The respiratory chain comprises
five complexes [8] (Fig. 1). Complex I (NADH-coenzyme Q
reductase) carries reducing equivalents from NADH to coenzyme
Q and consists of different polypeptides, seven of which are
encoded by mtDNA. Complex II (succinate-coenzyme Q reduc-
tase) carries reducing equivalents from FADH2 to coenzyme 0
and contains five polypeptides that are all encoded only by the
nuclear DNA. Complex III (reduced coenzyme Q-cytochrorne c
reductase) carries reducing equivalents from coenzyme 0 to
cytochrome c and contains 11 subunits, one of which is encoded by
mtDNA. Complex IV (cytochrome c oxidase, COX) transfers
reducing equivalents from cytochrome c to oxygen. This complex
is composed of cytochromes a and a3, and 13 protein subunits,
three of which are encoded by mtDNA. The fifth complex is ATP
synthetase [3]. Oxidative phosphorylation consists of oxidative
reactions that lead to oxygen consumption and phosphorylation of
ADP to ATP.
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Mitochondrial genome
Mitochondria contain their own DNA. The mitochondrial
genome is a small 16.5 kb circular double stranded DNA with an
asymmetric base composition (Fig. 2). The heavy strand (HS)
contains more guanine residues while the light strand (LS)
contains more cytosine residues. Each mitochondria contains 2 to
10 mtDNA molecules. The mtDNA contains 37 genes: 13 encode
for polypeptides of the respiratory chain, 2 for the ribosomal
RNAs (12S and 16S) and 22 for transfer RNAs [9, 10]. The 13
polypeptide-coding genes include genes encoding for seven sub-
units of complex I, one subunit of complex III, three subunits of
complex IV, and two subunits of complex V. These four enzymatic
complexes contain other polypeptides that are encoded by nuclear
DNA [11]. The subunits are imported from the cytoplasm in the
mitochondria. All complex II subunits as well as proteins involved
in the replication, the transcription and the translation of mtDNA
are encoded by the nuclear DNA. The replication, transcription
and translation of the mtDNA is independent of nuclear DNA.
There are two origins of replication of the mtDNA, an origin of
the heavy-strand replication (OH) located in a non-coding D-loop
region and an origin of light-strand replication (OL), while there
is only one promotor region for transcription also located in the
D-loop [12, 13]. Mitochondrial RNAs are translated on mitochon-
drial ribosomes.
Clinical features
Although mitochondrial diseases may begin at any age, in our
experience, the first symptoms are observed before one month of
age in more than one third of cases and before the age of two
years in 80% of cases [141. Table I summarizes the most frequent
symptoms observed in these disorders. An important feature in
these patients is the increasing number of tissues affected during
the course of the disease, with the central nervous system being
almost consistently involved in the late stage [14]. While the initial
symptoms often worsen with time, they may occasionally improve
or even disappear. Indeed, this has been described for myopathy
with hypotonia, pancytopenia or diarrhea in patients who subse-
quently developed other symptoms [15]. Such early reversible
symptoms should be looked for in patients who are diagnosed in
late childhood or adulthood. Some associations of clinical symp-
toms are more frequent and have been described as clinical
entities (Table 2). However, there is considerable overlap in
clinical features and it is often difficult to classify a given patient.
Myopathy is a frequent feature. It is responsible for muscle
weakness with myalgia and exercise intolerance [7]. Limb weak-
ness may be associated with chronic progressive external ophthal-
moplegia (PEO). The main features of PEO are ptosis, limitation
of eye movements and diplopia [7]. While PEO may be isolated,
it is often part of Kearns-Sayre syndrome (KSS) characterized by
the association of PEO, pigmentary retinopathy, ataxia and heart
block occurring before age 20 [16]. A number of patients present
with symptoms involving predominantly or exclusively the central
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Fig. 1. The mitochondrial respiratoty chain.
nervous system [4]. These symptoms consist psychomotor retar-
dation, seizures, stroke, sensorineural hearing loss, optic atrophy,
ataxia, myoclonus, peripheral neuropathy, dementia [17—19]. Sev-
eral clinicopathological entities such as KSS [16], MELAS (mito-
chondrial encephalomyopathy, lactic acidosis and stroke like
episodes) [20], MERRF (myoclonus epilepsy and ragged red
fibers) [21] have been described according to clinical presenta-
tions (Table 2). There are several reports of patients with overlap
syndromes such as KSS and MELAS [22, 23], KSS and MERRF
[24], PEO and MERRF [24—26], or MERRF and MELAS [27,
28]). Apart from myopathies and encephalopathies, there are a
number of non-neuromuscular manifestations that may occur in
patients with mitochondrial disorders. In addition to renal disor-
ders, endocrine glands may be involved with diabetes mellitus,
hypoparathyroidism, growth hormone deficiency [7, 29, 30]. Gas-
trointestinal symptoms include recurrent vomiting or colonic
pseudo-obstruction [31]. Cardiac involvement consists of conduc-
tion defects and concentric hypertrophic cardiomyopathy [32].
Some patients with isolated cardiomyopathy may remain undiag-
nosed [33]. Patients with Pearson syndrome suffer from refractory
sideroblastic anemia, thrombocytopenia, neutropenia, hepatocel-
lular dysfunction, proximal tubular dysfunction and exocrine
pancreas dysfunction [34, 35].
Renal disease is rare in adults but has been reported more
frequently in children. The most frequent renal manifestation is
proximal tubulopathy with a de Toni-Debré-Fanconi syndrome.
Other renal presentations have been reported, including glomer-
ular disease with a nephrotic syndrome and chronic tubulointer-
stitial nephropathy.
The de Toni-Debré-Fanconi syndrome is characterized by an
impairment of proximal tubular reabsorption, leading to urinary
losses of amino acids, glucose, proteins, phosphate, uric acid,
bicarbonate, potassium and water. A renal Fanconi syndrome
have been reported in 39 patients [15, 23, 29, 36—59]. Proximal
tubular losses are often moderate as in five patients only by-
peraminoaciduria was noted [23, 36, 46, 50, 55]. Other patients
present with plasma acidosis, impaired tubular phosphate reab-
sorption, moderate glycosuria, hypercalciuria and tubular protein-
uria. Of the 39 cases, 28 concerned females. The first symptoms of
the disease developed in the neonatal period in 13 patients and
before the age of two years in 32. Other siblings were affected in
12 cases, suggesting an autosomal recessive mode of inheritance
in 9 of them, whereas the mother of two girls was also affected as
she presented with myopathy and ophthalmoplegia. Moderate
renal failure was noted in 2 patients [47, 56]. A renal biopsy
specimen was available in 11 patients. It showed more or less
severe unspecific anomalies of tubular epithelium with dilations or
obliterations by casts, dedifferentiation or atrophy. Some tubular
cells showed cytoplasmic vacuolization. Giant mitochondria were
frequently observed. Extrarenal symptoms were present in all
patients. Twenty-one of them had myopathy, 22 had neurological
symptoms, 8 had hepatic dysfunction, 4 had the clinical features of
Pearson syndrome, 2 had signs of cardiac involvement and 3 had
diabetes mellitus. Seventeen of these patients died within the first
year of life.
Four children, aged 18 months to five years, had proximal
tubular acidosis with hypercalciuria in one [60—62]. Goto et a!
reported a five-year-old boy with Bartter syndrome [63]. All these
patients had various extrarenal symptoms (hearing loss, neurolog-
ical symptoms, growth retardation or diabetes mellitus).
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Table 1. Clinical symptoms observed in patients with mitochondrial
cytopathies
Affected organ Symptoms
Central nervous Apnea, lethargy, hypotonia, coma in the neonatal
system period, hypotonia, psychomotor regression,
cerebellar ataxia, stroke-like episodes, myoclonus,
seizures, dementia, spasticity, headache,
hemiparesis in infants and children
Muscle Myopathy, poor head control, limb weakness,
myalgia, exercise intolerance
Liver Liver enlargment, hepatocellular dysfunction
Heart Cardiomyopathy, heart block
Kidney Proximal tubulopathy, nephrotic syndrome, renal
failure, tubulointerstitial nephritis
Gut Vomiting, diarrhea, villous atrophy, colonic pseudo-
obstruction, exocrin pancreas dysfunction
Endocrine Diabetes mellitus, growth hormone deficiency,
hypoparathyroidism, hypothyroidism
Bone marrow Sideroblastic anemia, neutropenia,
thrombocytopenia
Ear Hearing loss
Eye Progressive external ophtalmoplegia, pigmentary
retinal degeneration, ptosis, diplopia, cataract
Skin Mottled pigmentation, trichothiodystrophy
Glomerular disease has been observed in a few patients with
mitochondrial cytopathies [37, 64]. Brun et a! [371 described two
girls aged 20 and 36 months with a nephrotic syndrome in whom
renal biopsy had shown focal and segmental glomerular sclerosis.
One of them had a decrease of glomerular filtration rate at nine
Fig. 2. Map of the mitochondrial genome.
Regions encoding cytochrome b (cyt b), various
subunits of NADH-coenzyme 0 reductase
(ND), cytochrome c oxidase (COX), ATPase,
and ribosomal RNAs (rRNA) are indicated.
years of age. Both patients in addition had myopathy, ophthalmo-
plegia, pigmentary retinopathy and hypoparathyroidism. Rotig et
al [641 also reported a patient with myopathy, pyramidal syndrome
and hearing loss who developed a nephrotic syndrome and focal
and segmental glomerular sclerosis and did not respond to
therapy.
Renal disease in patients with mitochondrial cytopathies may
consist of tubulointerstitial nephritis. Six patients with chronic
renal insufficiency without proximal tubular losses have been
reported [29, 37, 44, 65, 66]. Renal biopsy in tvo patients showed
diffuse interstitial fibrosis with tubular atrophy and sclerosed
glomeruli within the area of interstitial fibrosis. Al! patients
developed extrarenal symptoms including hearing loss, cardiomy-
opathy, myopathy, ataxia, developmental delay, ophthalmoplegia
and diabetes mellitus.
Finally, a few patients with diabetes mellitus have mitochon-
drial disorders [67—69]. Patients with Kearns-Sayre syndrome,
MELAS syndrome and Wolfram syndrome may develop diabetes
mellitus [2, 53, 70]. A mutation of mtDNA, involving the substi-
tution of guanine for arginine at position 3243 of tRNA
leu(UUR), have been described in several families with mater-
nally transmitted diabetes as well as in sporadic cases with
insulin-dependent diabetes mellitus or with non-insulin depen-
dent diabetes mellitus [37, 68, 71—73]. This mutation was also
reported in a family with maternally inherited cardiomyopathy,
diabetes mellitus, sensorineural deafness and renal failure that
was not related to diabetes mellitus [74]. It may be postulated that
mutations of mtDNA in pancreatic /3 cells contribute to the
development of diabetes mellitus.
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Table 2. Clinicopathologic entities in mitochondrial cytopathies
Kearns-Sayre syndrome Progressive external ophthalmoplegia, retinal pigmentary degeneration,
cerebellar ataxia, heart block
MERRF (myoclonus epilepsy and ragged red fibers) Encephalomyopathy with myoclonus, epilepsy, ataxia, myopathy, hearing
loss and dementia
LHON (Leber hereditary optic neuropathy) Blindness, cardiac dysrythmia
MELAS (mitochondrial encephalomyopathy, lactic acidosis and Headache, vomitings, lactic acidosis, myopathy with ragged red fibers,
stroke-like episodes) seizures, dementia, deafness
Leigh disease Subacute necrotizing encephalomyopathy, ataxia, respiratory troubles with
weak ely, deafness, blindness
CPEO (chronic progressive external ophthalmoplegia) and Ocular myopathy, retinal pigmentary degeneration, central nervous system
mitochondrial myopathy dysfunction
Alpers disease Progressive infantile poliodystrophy, hepatic failure
Metabolic investigations and enzymatic studies
An enzymatic deficiency of the respiratory chain results in an
increase of reducing equivalents (NADH, FADH) in both mito-
chondria and cytoplasm and the functional impairment of the
Krebs cycle. In the mitochondrion, the excess of NADH induces
the transformation of acetoacetate to 3-hydroxybutyrate with a
concomitant increase of the ratio 3-hydroxybutyrate/acetoacetate.
Similarly, in the cytoplasm, pyruvate is transformed in lactate
resulting in an increased molar ratio of lactate/pyruvate with a
secondary increase of blood lactate. These abnormalities are more
pronounced during the post absorptive period or after an exercise,
when more NAD is required to oxidize glycolytic substrates [75].
Similarly, because of the functional impairment of the Krebs
cycle, ketone body synthesis increases due to the channeling of
acetyl CoA towards ketogenesis. The increase of ketone bodies
after a meal is paradoxical as it normally decreases following
insulin release. Therefore, a persistent hyperlactacidemia, an
impaired redox status and a paradoxical ketonemia are highly
suggestive of a respiratory chain defect.
It should be stressed that these metabolic abnormalities may
not be present in patients with proximal tubulopathy as impaired
proximal tubular functions may lower blood lactate and increase
urinary lactate. In such cases, gas chromatography-mass spectro-
photometry can detect high amounts of urinary lactate and Krebs
cycle intermediates.
The activity of the different enzymatic complexes can be
estimated by polarographic and spectrophotometric studies.
These studies can be performed on any tissue or organ but it is
recommended to test one which is affected by the disease [761.
Therefore, in the case of renal involvement, a renal biopsy can be
proposed. However, other tissues may be more accessible, such as
skeletal muscle, cultured skin fibroblasts or peripheral blood
lymphocytes. Polarographic studies measure oxygen consumption
by isolated mitochondria or whole cells in the presence of
different oxidative substrates such as pyruvate, glutamate, succi-
nate, etc. [77, 78]. Enzyme activities are assessed by spectropho-
tometsy [79]. These techniques permit an identification of any
enzymatic defect. Enzymological studies of the mitochondrial
respiratory chain most often allow the diagnosis of mitochondrial
disorders.
Genetics
Mitochondria are transmitted through the egg cytoplasm. As
only nuclear DNA from the spermatozoid is retained during the
fecondation, cytoplasmic heredity is in fact a maternal heredity
[80]. The mothers transmit their mtDNA to all their progeny and
the daughters transmit their mtDNA to the next generation.
Males never transmit their mtDNA. This feature accounts for the
maternal inheritance of mtDNA mutations.
All human cells contain several mitochondria. In most cases,
mtDNA copies in each mitochondrion are identical, a condition
named homoplasmy. When a mtDNA mutation arises, it creates a
mixture of normal and mutant molecules called heteroplasmy
(Fig. 3) [81]. However, it is impossible to determine if the two
types of mtDNA coexist in the same mitochondrium or in the
same cell. Heteroplasmy is almost constant in case of mitochon-
dna! cytopathy. During mitotic cell division, mitochondria are
randomly partitioned to daughter cells. If normal and mutant
mtDNA are present in mother cells, some daughter cells may drift
towards purely mutant mtDNA or purely normal mtDNA while
others remain heteroplasmic. The phenotype is defined not only
by the nature of the mutation but also by the amount of mutated
mtDNA in a given tissue. In cells with both wild-type and mutant
mtDNA, the phenotype depends on the proportion of mutant
mtDNA molecules and the extent at which the cell type relies on
mitochondrial function. A tissue with only 20% of mutated
mtDNA may have a normal phenotype. As the phenotype of a
given tissue may vary during the course of the disease according to
the proportion of mutant/wild-type mtDNA, clinical symptoms
related to an affected organ may worsen or improve and even
disappear with time, while other organs become involved. In
mitochondrial disorders, children in the same family may not be
all clinically affected. Even if siblings may all have the same
mutation, the proportion of mutated molecules may vary from
one child to another and give rise to different phenotypes.
Any mode of inheritance may be observed in mitochondrial
diseases: autosomal recessive, dominant, X-linked, maternal or
sporadic. This variability is due to the high number of genes that
encode for the respiratory chain proteins. Most of these genes are
located in the nucleus and only 13 in the mitochondrion. How-
ever, mtDNA has a high mutation rate that may explain the
frequency of mitochondrial disorders.
Point mutations of mtDNA result in amino acid substitutions
and mutations of niRNA and tRNA. Most of them are maternally
inherited and heteroplamic. They are associated with a wide range
of clinical phenotypes including Leber's hereditary optic neurop-
athy (LHON) [821, MERRF [83], MELAS [84], mitochondrial
myopathy and cardiomyopathy [85], Leigh syndrome [86], neu-
ropathy, ataxia and retinitis pigmentosa (NARP) [87].
Deletions-duplications of the mtDNA genome differ in size and
position from patient to patient and usually encompass several
coding and tRNA genes. They are often sporadic and probably
Mitochondrion
Cell Wild-type mtDNA
Mutant mtDNA
+
Cell divisions
Homoplasmy Heteroplasmy Homoplasmy
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occur de novo during oogenesis or in early development. Large
deletions, of 2 to 10 kb, were first reported in patients with
mitochondrial myopathies, Kearns-Sayre syndrome and progres-
sive external ophthalmoplegia [40, 88, 891. The size and the
location of these giant deletions are not related to the severity of
the disease nor to the clinical symptoms [90]. One of them, the
common deletion, is more often found. This 4977 bp deletion has
been reported in patients with KSS and in patients with Pearson
syndrome [91, 92]. Interestingly, patients with the Pearson syn-
drome who survive may develop symptoms of KSS [15]. The
deleted mtDNA is more prominent in the blood after birth,
leading to pancytopenia in patients with the Pearson's syndrome,
but it may progressively accumulate in the muscle during the life
with clinical signs of myopathy [93]. Duplications of mtDNA have
been identified in KSS and in a patient with proximal tubulopathy
[53, 94]. It is beleived that duplications of mtDNA have the same
consequences as the deletions [95]. Occasionally, maternally
transmitted mtDNA rearrangements can occur.
Mitochondrial DNA depletions due to a decreased number of
mtDNA copies have been also described in cases of lethal
infantile respiratory, liver and kidney disease with an autosomal
recessive mode of inheritance [96]. Little is known about the
mutations of the nuclear DNA. Only one mutation has been
described in a nuclear gene of succinate deshydrogenase (complex
II) in two sisters presenting with Leigh syndrome [97].
Other deletions of mtDNA have been reported in patients with
mitochondrial disorders and renal involvement. Deletions ranging
from 2.7 to 6.9 kb in muscle, lymphocytes or kidney tissue were
found in 8 patients with a Fanconi syndrome [15, 23, 40, 44, 45, 48,
50]. Eviatar et at [60] found a 7.5 kb deletion in a patient with
tubular acidosis and Goto et at [63] reported a patient with
Bartter syndrome and a 8.8 kb deletion in muscle and kidney
mtDNA.
Fig. 3. Mitotic segregation of mtDNA,
homoplasmy and heteroplasmy.
Treatment
No satisfactory treatment is presently available to alter the
course of mitochondrial disorders. The treatment is mainly symp-
tomatic. It includes avoidance of drugs that are known to interfere
with the respiratory chain and may precipitate hepatic failure such
as valproate and barbiturates. Tetracyclines and chloramphenicol,
which inhibit mitochondrial protein synthesis, should also be
avoided [981. Lactic acidosis may be exacerbated by exercise or
intercurrent infection and should be treated with slow infusion
with sodium bicarbonate. Some patients may require pancreatic
extracts in case of exocrine pancreas dysfunction or blood trans-
fusions in case of anemia or thrombopenia.
Patients with complex III deficiency may be improved with
vitamin K3 (40 to 160 mg/day) or coenzyme Q10 (80 to 300
mg/day) [99]. Patients with complex I deficiency myopathy may be
treated with ribofiavine (100 mg/day). Carnitine supplements are
given in case of secondary carnitine deficiency. The prevention of
oxygen radical damage is the rationale for ascorbate administra-
tion [100]. Dietary recommendations include a high lipid and low
carbohydrate diet in patients with complex I deficiency. Hyperca-
lone diet and parenteral nutrition should be avoided in these
patients.
Supplements of sodium bicarbonate, potassium, vitamin D,
phosphorus and water may he necessary in patients with proximal
tubular losses.
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